Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Kevetrin displayed a broad spectrum anticancer activity in xenograft
tumor models (lung, breast, colon, prostate, squamous cell,
and leukemia),while being well tolerated with low toxicity.

IMO. Since oustanding results and low toxicity was demonstrated in human xenograft mouse studies, Dr Frei with DF knew Cellceutix had a winner with Kevetrin for testing on late stage multi drug resistant cancer patients.